Categorized | Opinion Editorial

Should QbD Practices Be Patented?

    Should QbD Practices Be Patented?

    by Agnes Shanley

    Recently we heard of a very smart PAT/QbD route being patented, but that news only seemed to beg the question of whether  giving exclusivity to a few companies would impede further adoption of QbD within the industry. Does it stimulate or prevent good scientific practices and could it, in the long term, hurt patients in the future?  Here’s an editorial on this topic that was published in Pharmaceutical Manufacturing.  What are your thoughts?

    Related posts:

    1. Modelers Gone Wild: Six Practices to Prevent
      Pfizer's Joe Cancelarich, director of global engineering, shares six ways that drug industry simulation modelers go wrong. ...
    2. Video: Got Goat? First Approved Drug from Engineered Animal
      FDA recently approved the first biological product made from genetically engineered animals. The product, called ATryn, is an anticoagulant used...
    3. Pharma Faces a New Year: Will it Mirror, or Break Away From, the Past?
      Effective change in the pharmaceutical industry must improve business performance, and not just a process. Ali Afnan anticipates what must...

    Leave a Reply

    You must be logged in to post a comment.